NASDAQ:ARQL - ArQule Stock Price, Price Target & More

$2.87 -0.08 (-2.71 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$2.87
Today's Range$2.87 - $3.0650
52-Week Range$0.92 - $3.35
Volume1.01 million shs
Average Volume735,312 shs
Market Capitalization$272.65 million
P/E Ratio-7.36
Dividend YieldN/A
Beta0.83

About ArQule (NASDAQ:ARQL)

ArQule logoArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. Its lead product candidate is tivantinib (ARQ 197), a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer. The company's clinical-stage products include ARQ 087, a multi-kinase inhibitor of the fibroblast growth factor receptor (FGFR) family Phase II clinical trial for patients with intrahepatic cholangiocarcinoma and in Phase Ib for multiple oncology indications; ARQ 092, an inhibitor of the AKT serine/threonine kinase in Phase I clinical trials for multiple oncology indications; ARQ 751, a next-generation inhibitor of AKT in Phase I clinical trial for solid tumors; and ARQ 761, an intravenously administered analogue of Beta-lapachone, which is Phase 1b clinical trial used as a promoter of NQo1-mediated programmed cancer cell death. Its pre-clinical development program also includes ARQ 531, an inhibitor of Bruton's tyrosine kinase. The company has co-development and co-commercialization agreement with Daiichi Sankyo Co., Ltd.; license agreement with Kyowa Hakko Kirin Co., Ltd.; and collaborative research and development agreement with Beryllium Development Corp. ArQule, Inc. also has a collaboration agreement with Roivant Sciences Ltd. to develop derazantinib, a pan-FGFR inhibitor in Greater China. The company was founded in 1993 and is headquartered in Burlington, Massachusetts.

Receive ARQL News and Ratings via Email

Sign-up to receive the latest news and ratings for ARQL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ARQL
CUSIP04269E10
Phone781-994-0300

Debt

Debt-to-Equity Ratio1.03%
Current Ratio4.98%
Quick Ratio4.98%

Price-To-Earnings

Trailing P/E Ratio-7.36
Forward P/E Ratio-9.26
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.71 million
Price / Sales53.08
Cash FlowN/A
Price / CashN/A
Book Value$0.16 per share
Price / Book17.94

Profitability

EPS (Most Recent Fiscal Year)($0.39)
Net Income$-29,200,000.00
Net MarginsN/A
Return on Equity-247.01%
Return on Assets-79.25%

Miscellaneous

Employees32
Outstanding Shares87,110,000

How to Become a New Pot Stock Millionaire

ArQule (NASDAQ:ARQL) Frequently Asked Questions

What is ArQule's stock symbol?

ArQule trades on the NASDAQ under the ticker symbol "ARQL."

How were ArQule's earnings last quarter?

ArQule, Inc. (NASDAQ:ARQL) released its quarterly earnings data on Monday, March, 5th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.09). During the same period in the prior year, the business earned ($0.10) EPS. View ArQule's Earnings History.

When is ArQule's next earnings date?

ArQule is scheduled to release their next quarterly earnings announcement on Tuesday, May, 1st 2018. View Earnings Estimates for ArQule.

What price target have analysts set for ARQL?

4 equities research analysts have issued 12-month price targets for ArQule's shares. Their predictions range from $4.00 to $6.00. On average, they anticipate ArQule's share price to reach $5.00 in the next year. View Analyst Ratings for ArQule.

Are investors shorting ArQule?

ArQule saw a increase in short interest in March. As of March 15th, there was short interest totalling 1,599,791 shares, an increase of 128.8% from the February 28th total of 699,076 shares. Based on an average trading volume of 515,326 shares, the short-interest ratio is currently 3.1 days. Currently, 2.0% of the company's stock are sold short.

Who are some of ArQule's key competitors?

Who are ArQule's key executives?

ArQule's management team includes the folowing people:
  • Mr. Paolo Pucci, Chief Exec. Officer and Director (Age 57)
  • Mr. Peter S. Lawrence, Pres, COO & Sec. (Age 55)
  • Mr. Robert J. Weiskopf, CFO & Treasurer (Age 67)
  • Dr. Brian Schwartz M.D., Chief Medical Officer (Age 56)
  • Dawn Schottlandt CFA, Sr. Director of Investor Relations & Corp. Communications

Has ArQule been receiving favorable news coverage?

Media stories about ARQL stock have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ArQule earned a news impact score of 0.11 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 45.50 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.

How do I buy shares of ArQule?

Shares of ARQL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ArQule's stock price today?

One share of ARQL stock can currently be purchased for approximately $2.87.

How big of a company is ArQule?

ArQule has a market capitalization of $272.65 million and generates $4.71 million in revenue each year. The biotechnology company earns $-29,200,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. ArQule employs 32 workers across the globe.

How can I contact ArQule?

ArQule's mailing address is ONE WALL STREET, BURLINGTON MA, 01803. The biotechnology company can be reached via phone at 781-994-0300 or via email at [email protected]


MarketBeat Community Rating for ArQule (ARQL)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  157 (Vote Outperform)
Underperform Votes:  144 (Vote Underperform)
Total Votes:  301
MarketBeat's community ratings are surveys of what our community members think about ArQule and other stocks. Vote "Outperform" if you believe ARQL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARQL will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ArQule (NASDAQ:ARQL) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for ArQule in the last 12 months. Their average twelve-month price target is $5.00, suggesting that the stock has a possible upside of 74.22%. The high price target for ARQL is $6.00 and the low price target for ARQL is $4.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 3.003.003.00N/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.00$4.00N/AN/A
Price Target Upside: 74.22% upside139.52% upsideN/AN/A

ArQule (NASDAQ:ARQL) Consensus Price Target History

Price Target History for ArQule (NASDAQ:ARQL)

ArQule (NASDAQ:ARQL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/17/2018Roth CapitalBoost Price TargetBuy$5.00 -> $6.00HighView Rating Details
4/5/2018Leerink SwannUpgradeMarket Perform -> OutperformMediumView Rating Details
3/26/2018B. RileySet Price TargetBuy$4.00HighView Rating Details
12/14/2017Needham & Company LLCUpgradeHold -> BuyHighView Rating Details
(Data available from 4/20/2016 forward)

Earnings

ArQule (NASDAQ:ARQL) Earnings History and Estimates Chart

Earnings by Quarter for ArQule (NASDAQ:ARQL)

ArQule (NASDAQ:ARQL) Earnings Estimates

2018 EPS Consensus Estimate: ($0.30)
2019 EPS Consensus Estimate: ($0.34)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.05)($0.05)($0.05)
Q2 20182($0.09)($0.09)($0.09)
Q3 20182($0.09)($0.09)($0.09)
Q4 20182($0.08)($0.07)($0.07)
Q1 20191($0.10)($0.10)($0.10)
Q2 20191($0.09)($0.09)($0.09)
Q3 20191($0.09)($0.09)($0.09)
Q4 20191($0.06)($0.06)($0.06)

ArQule (NASDAQ ARQL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2018($0.07)N/AView Earnings Details
3/5/2018Q4 2017($0.09)($0.09)ViewListenView Earnings Details
11/9/2017Q3 2017($0.11)($0.09)ViewN/AView Earnings Details
8/4/2017Q2 2017($0.11)($0.10)ViewN/AView Earnings Details
5/3/2017Q1 2017($0.1070)($0.11)ViewListenView Earnings Details
3/7/2017Q4 2016($0.10)($0.10)$1.20 million$1.19 millionViewListenView Earnings Details
11/7/2016Q316($0.09)($0.08)$1.10 million$1.22 millionViewListenView Earnings Details
8/3/2016Q216($0.08)($0.07)$1.13 million$1.07 millionViewN/AView Earnings Details
5/4/2016Q116($0.07)($0.08)$1.63 million$1.28 millionViewN/AView Earnings Details
2/29/2016Q415($0.06)($0.05)$2.40 million$2.80 millionViewListenView Earnings Details
11/4/2015Q315($0.08)($0.04)$2.60 million$2.65 millionViewN/AView Earnings Details
8/5/2015Q215($0.08)($0.06)$2.50 million$3.04 millionViewN/AView Earnings Details
5/6/2015Q115($0.08)($0.07)$1.98 million$2.79 millionViewN/AView Earnings Details
3/4/2015Q414($0.13)($0.06)$1.90 million$3.02 millionViewN/AView Earnings Details
11/10/2014Q314($0.13)($0.10)$2.20 million$2.66 millionViewN/AView Earnings Details
8/5/2014Q214($0.13)($0.10)$2.43 million$2.90 millionViewN/AView Earnings Details
5/7/2014Q114($0.11)($0.11)$2.29 million$2.67 millionViewN/AView Earnings Details
3/5/2014Q413($0.13)($0.10)$2.27 million$2.28 millionViewN/AView Earnings Details
10/31/2013Q313($0.13)($0.10)$2.77 million$3.50 millionViewN/AView Earnings Details
7/30/2013Q2 2013($0.12)($0.11)$3.84 million$4.44 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.11)($0.09)$3.78 million$5.66 millionViewN/AView Earnings Details
3/14/2013Q4 2012($0.13)($0.09)$5.17 million$5.14 millionViewN/AView Earnings Details
11/1/2012($0.07)($0.01)ViewN/AView Earnings Details
8/2/2012($0.07)($0.01)ViewN/AView Earnings Details
5/3/2012($0.07)($0.08)ViewN/AView Earnings Details
3/1/2012($0.09)$0.07ViewN/AView Earnings Details
11/10/2011($0.23)($0.04)ViewN/AView Earnings Details
8/4/2011($0.19)($0.20)ViewN/AView Earnings Details
5/5/2011($0.08)($0.03)ViewN/AView Earnings Details
3/1/2011($0.15)($0.13)ViewN/AView Earnings Details
11/9/2010Q3 2010($0.19)($0.14)ViewN/AView Earnings Details
8/4/2010Q2 2010($0.20)($0.18)ViewN/AView Earnings Details
5/6/2010Q1 2010($0.21)($0.22)ViewN/AView Earnings Details
3/2/2010Q4 2009($0.25)($0.22)ViewN/AView Earnings Details
11/5/2009Q3 2009($0.26)($0.19)ViewN/AView Earnings Details
8/6/2009Q2 2009($0.23)($0.22)ViewN/AView Earnings Details
5/7/2009Q1 2009($0.21)($0.23)ViewN/AView Earnings Details
3/5/2009Q4 2008($0.27)($0.22)ViewN/AView Earnings Details
11/10/2008Q3 2008($0.42)($0.26)ViewN/AView Earnings Details
8/11/2008Q2 2008($0.38)($0.37)ViewN/AView Earnings Details
5/12/2008Q1 2008($0.35)($0.32)ViewN/AView Earnings Details
2/7/2008Q4 2007($0.31)($0.33)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

ArQule (NASDAQ:ARQL) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

ArQule (NASDAQ ARQL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.90%
Institutional Ownership Percentage: 67.14%
Insider Trading History for ArQule (NASDAQ:ARQL)
Institutional Ownership by Quarter for ArQule (NASDAQ:ARQL)

ArQule (NASDAQ ARQL) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/18/2018Value Fund L P BiotechnologyInsiderSell2,230,373$3.10$6,914,156.30View SEC Filing  
4/4/2018Value Fund L P BiotechnologyInsiderSell2,301,581$2.90$6,674,584.90View SEC Filing  
9/7/2017Paolo PucciCEOBuy1,101$1.15$1,266.15404,194View SEC Filing  
9/6/2017Paolo PucciCEOBuy16,397$1.15$18,856.55403,093View SEC Filing  
9/5/2017Paolo PucciCEOBuy19,156$1.14$21,837.84386,696View SEC Filing  
8/29/2017Paolo PucciCEOBuy300$1.05$315.00367,540View SEC Filing  
8/28/2017Paolo PucciCEOBuy2,970$1.05$3,118.50367,240View SEC Filing  
8/25/2017Paolo PucciInsiderBuy9,492$1.05$9,966.60363,569View SEC Filing  
12/17/2015Michael D LobergDirectorBuy3,719$2.16$8,033.04132,142View SEC Filing  
12/16/2015Michael D LobergDirectorBuy1,231$2.14$2,634.34128,423View SEC Filing  
12/15/2015Paolo PucciCEOBuy1,283$2.16$2,771.28257,280View SEC Filing  
12/11/2015Paolo PucciCEOBuy1,108$2.10$2,326.80255,997View SEC Filing  
12/11/2015Patrick J ZennerDirectorBuy2,300$2.15$4,945.00View SEC Filing  
12/10/2015Paolo PucciCEOBuy7,609$2.10$15,978.90254,889View SEC Filing  
3/11/2015Patrick J ZennerDirectorBuy10,625$2.32$24,650.00View SEC Filing  
11/20/2014Paolo PucciCEOBuy5,000$1.26$6,300.00View SEC Filing  
11/14/2014Patrick J ZennerDirectorBuy20,830$1.20$24,996.00View SEC Filing  
11/13/2014Susan L KelleyDirectorBuy50,000$1.20$60,000.00View SEC Filing  
9/4/2014Paolo PucciCEOBuy5,000$1.31$6,550.00View SEC Filing  
5/23/2014Paolo PucciCEOBuy5,000$1.40$7,000.00View SEC Filing  
5/20/2014Paolo PucciCEOBuy5,000$1.42$7,100.00232,280View SEC Filing  
3/17/2014Patrick ZennerDirectorBuy4,715$2.12$9,995.80View SEC Filing  
3/13/2014Paolo PucciCEOBuy10,000$2.10$21,000.00227,280View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

ArQule (NASDAQ ARQL) News Headlines

Source:
DateHeadline
Insider Selling: ArQule, Inc. (ARQL) Insider Sells 2,230,373 Shares of StockInsider Selling: ArQule, Inc. (ARQL) Insider Sells 2,230,373 Shares of Stock
www.americanbankingnews.com - April 20 at 7:22 PM
ArQule, Inc. (ARQL) Expected to Announce Earnings of -$0.06 Per ShareArQule, Inc. (ARQL) Expected to Announce Earnings of -$0.06 Per Share
www.americanbankingnews.com - April 19 at 9:09 AM
ArQule (ARQL) PT Raised to $6 at Roth Capital, A Cleaner Story Going ForwardArQule (ARQL) PT Raised to $6 at Roth Capital, 'A Cleaner Story Going Forward'
www.streetinsider.com - April 18 at 8:45 AM
ArQule, Inc. (ARQL) Receives Consensus Recommendation of "Buy" from BrokeragesArQule, Inc. (ARQL) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 18 at 3:38 AM
Health Care Sector Update for 04/17/2018: ARQL,NCVR,JNJ,CLVSHealth Care Sector Update for 04/17/2018: ARQL,NCVR,JNJ,CLVS
www.nasdaq.com - April 17 at 5:31 PM
ArQule (ARQL) Price Target Raised to $6.00ArQule (ARQL) Price Target Raised to $6.00
www.americanbankingnews.com - April 17 at 1:23 PM
Biotech Forum: The Week AheadBiotech Forum: The Week Ahead
seekingalpha.com - April 17 at 9:04 AM
BRIEF-Arqule And Basilea Enter Into Exclusive License Agreement For DerazantinibBRIEF-Arqule And Basilea Enter Into Exclusive License Agreement For Derazantinib
www.reuters.com - April 17 at 9:04 AM
Basilea licenses late-stage oncology drug candidate derazantBasilea licenses late-stage oncology drug candidate derazant
www.lse.co.uk - April 17 at 9:04 AM
ArQule and Basilea Enter into Exclusive License Agreement for Derazantinib in the US, EU, Japan and Rest of World Excluding Greater ChinaArQule and Basilea Enter into Exclusive License Agreement for Derazantinib in the US, EU, Japan and Rest of World Excluding Greater China
finance.yahoo.com - April 17 at 9:04 AM
Basilea licenses late-stage oncology drug candidate derazantinib from ArQuleBasilea licenses late-stage oncology drug candidate derazantinib from ArQule
feeds.benzinga.com - April 17 at 1:51 AM
ArQule (ARQL) Upgraded by Zacks Investment Research to "Buy"ArQule (ARQL) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 16 at 6:30 PM
ArQule, Inc. Is Moving On ASCO Release, Here’s Why.ArQule, Inc. Is Moving On ASCO Release, Here’s Why.
finance.yahoo.com - April 16 at 5:01 PM
ArQule (ARQL) Downgraded to "Hold" at Zacks Investment ResearchArQule (ARQL) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 13 at 5:29 PM
Bristol-Myers Investors Set Their Sights on Next Weeks Cancer Drug ShowdownBristol-Myers Investors Set Their Sights on Next Week's Cancer Drug Showdown
www.bloomberg.com - April 12 at 5:09 PM
ArQule, Inc. (ARQL) to Post Q1 2018 Earnings of ($0.05) Per Share, Leerink Swann ForecastsArQule, Inc. (ARQL) to Post Q1 2018 Earnings of ($0.05) Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - April 9 at 1:39 AM
ArQule (ARQL) Downgraded by BidaskClub to BuyArQule (ARQL) Downgraded by BidaskClub to Buy
www.americanbankingnews.com - April 7 at 7:02 AM
ArQule, Inc. (ARQL) Insider Sells $6,674,584.90 in StockArQule, Inc. (ARQL) Insider Sells $6,674,584.90 in Stock
www.americanbankingnews.com - April 6 at 7:14 PM
ArQule (ARQL) Upgraded at Zacks Investment ResearchArQule (ARQL) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 6 at 5:52 PM
ArQule (ARQL) Stock Rating Upgraded by Leerink SwannArQule (ARQL) Stock Rating Upgraded by Leerink Swann
www.americanbankingnews.com - April 5 at 12:27 PM
ArQule (ARQL) Lowered to "Hold" at Zacks Investment ResearchArQule (ARQL) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 4 at 5:52 PM
$2.27 Million in Sales Expected for ArQule, Inc. (ARQL) This Quarter$2.27 Million in Sales Expected for ArQule, Inc. (ARQL) This Quarter
www.americanbankingnews.com - April 4 at 4:22 AM
Will ArQule (ARQL) Continue to Surge Higher? April 02, 2018Will ArQule (ARQL) Continue to Surge Higher? April 02, 2018
www.zacks.com - April 2 at 5:05 PM
Will ArQule (ARQL) Continue to Surge Higher?Will ArQule (ARQL) Continue to Surge Higher?
finance.yahoo.com - April 2 at 9:10 AM
 Analysts Anticipate ArQule, Inc. (ARQL) Will Announce Earnings of -$0.06 Per Share Analysts Anticipate ArQule, Inc. (ARQL) Will Announce Earnings of -$0.06 Per Share
www.americanbankingnews.com - April 2 at 7:28 AM
ArQule (ARQL) Upgraded to Buy at Zacks Investment ResearchArQule (ARQL) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - March 30 at 5:40 PM
ArQule, Inc. (ARQL) Short Interest Up 128.8% in MarchArQule, Inc. (ARQL) Short Interest Up 128.8% in March
www.americanbankingnews.com - March 30 at 2:27 AM
Research Analysts Issue Forecasts for ArQule, Inc.s Q2 2018 Earnings (ARQL)Research Analysts Issue Forecasts for ArQule, Inc.'s Q2 2018 Earnings (ARQL)
www.americanbankingnews.com - March 28 at 7:01 AM
ArQule, Inc. (ARQL) to Post Q1 2019 Earnings of ($0.10) Per Share, B. Riley ForecastsArQule, Inc. (ARQL) to Post Q1 2019 Earnings of ($0.10) Per Share, B. Riley Forecasts
www.americanbankingnews.com - March 27 at 7:52 AM
ArQule (ARQL) Given a $4.00 Price Target at B. RileyArQule (ARQL) Given a $4.00 Price Target at B. Riley
www.americanbankingnews.com - March 26 at 1:24 PM
BidaskClub Upgrades ArQule (ARQL) to Strong-BuyBidaskClub Upgrades ArQule (ARQL) to Strong-Buy
www.americanbankingnews.com - March 24 at 10:59 AM
ArQule, Inc. (ARQL) Given Consensus Recommendation of "Buy" by BrokeragesArQule, Inc. (ARQL) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 24 at 3:48 AM
ArQule (ARQL) Rating Lowered to Hold at Zacks Investment ResearchArQule (ARQL) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - March 21 at 4:40 PM
Cytokinetics (CYTK) vs. ArQule (ARQL) Head-To-Head ComparisonCytokinetics (CYTK) vs. ArQule (ARQL) Head-To-Head Comparison
www.americanbankingnews.com - March 21 at 10:38 AM
ArQule (ARQL) Upgraded to "Buy" by Zacks Investment ResearchArQule (ARQL) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - March 20 at 5:56 PM
ArQule to Present at the 17th Annual Needham Healthcare Conference on March 27, 2018ArQule to Present at the 17th Annual Needham Healthcare Conference on March 27, 2018
finance.yahoo.com - March 20 at 9:00 AM
ArQule, Inc. (ARQL) Expected to Announce Quarterly Sales of $1.90 MillionArQule, Inc. (ARQL) Expected to Announce Quarterly Sales of $1.90 Million
www.americanbankingnews.com - March 18 at 8:06 AM
ArQule (ARQL) in Focus: Stock Moves 15.6% HigherArQule (ARQL) in Focus: Stock Moves 15.6% Higher
finance.yahoo.com - March 16 at 6:04 PM
FDAs BTD tag for J&Js erdafitinib stokes buying in competitor ArQule; shares up 12%FDA's BTD tag for J&J's erdafitinib stokes buying in competitor ArQule; shares up 12%
seekingalpha.com - March 16 at 3:43 PM
ArQule to Present Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting - Business Wire (press release)ArQule to Present Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting - Business Wire (press release)
www.businesswire.com - March 16 at 8:53 AM
 Analysts Anticipate ArQule, Inc. (ARQL) to Announce -$0.06 EPS Analysts Anticipate ArQule, Inc. (ARQL) to Announce -$0.06 EPS
www.americanbankingnews.com - March 16 at 5:16 AM
ArQule (ARQL) Stock Rating Upgraded by ValuEngineArQule (ARQL) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 16 at 12:48 AM
ArQule to Present Data at the 2018 American Association for Cancer Research (AACR) Annual MeetingArQule to Present Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - March 15 at 8:42 AM
FY2018 Earnings Estimate for ArQule, Inc. Issued By Leerink Swann (ARQL)FY2018 Earnings Estimate for ArQule, Inc. Issued By Leerink Swann (ARQL)
www.americanbankingnews.com - March 8 at 9:27 AM
ArQule, Inc. (ARQL) Expected to Post Q1 2018 Earnings of ($0.05) Per ShareArQule, Inc. (ARQL) Expected to Post Q1 2018 Earnings of ($0.05) Per Share
www.americanbankingnews.com - March 7 at 7:58 AM
ArQule Reports Fourth Quarter and Full Year 2017 Financial ResultsArQule Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 5 at 5:32 PM
ArQule to Present at the 30th Annual Roth Conference on March 12, 2018ArQule to Present at the 30th Annual Roth Conference on March 12, 2018
finance.yahoo.com - March 5 at 5:32 PM
With A -50.74% Earnings Drop, Is ArQule Inc’s (NASDAQ:ARQL) Performance A Concern?With A -50.74% Earnings Drop, Is ArQule Inc’s (NASDAQ:ARQL) Performance A Concern?
finance.yahoo.com - March 5 at 5:32 PM
ArQule (ARQL) Announces Quarterly  Earnings Results, Hits ExpectationsArQule (ARQL) Announces Quarterly Earnings Results, Hits Expectations
www.americanbankingnews.com - March 5 at 8:54 AM
Head to Head Contrast: ArQule (ARQL) versus Editas Medicine (EDIT)Head to Head Contrast: ArQule (ARQL) versus Editas Medicine (EDIT)
www.americanbankingnews.com - March 4 at 1:32 PM

SEC Filings

ArQule (NASDAQ:ARQL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

ArQule (NASDAQ:ARQL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

ArQule (NASDAQ ARQL) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.